



Better Health, Brighter Future

The background of the cover is a photograph of a woman kneeling and talking to a young child in a large, bright room with floor-to-ceiling windows. The windows look out onto a lush green forest. A large red rectangular area is overlaid on the left side of the image, containing the title text.

CORPORATE PROFILE 2017

Takeda Pharmaceutical Company Limited

CONTENTS

01 — OUR VALUES

Who We Are 6

Our Heritage, Our Future 8

02 — OUR PEOPLE

A Message from our CEO 16

Corporate Governance 18

Board of Directors 19

Takeda Executive Team 20

Diverse Perspectives 22

Talent Development 24

03 — RESEARCH & DEVELOPMENT

Our Research 28

Partnerships and Collaborations 30

04 — BUSINESS PERFORMANCE

FY2016 Underlying Growth 34

Takeda's Growth Drivers 35

Corporate Social Responsibility (CSR) 36

Takeda's Global CSR Program 38

Access to Medicines 40



Takeda's Shonan Research Center is located between Kamakura and Fujisawa, about 50km south of Tokyo. The campus also includes a day-care center for employees children, and is surrounded by a rich variety of trees and wildlife. It is also home to the Shonan Health Innovation Park, which we aspire to become the leading hub for Japan's biopharmaceutical ecosystem.

TAKEDA.COM

Published July 2017

Takeda Pharmaceutical Company Limited

01 VALUES

Takeda-ism and Our Priorities



Originally built in 1932 as a residence for Chobei VI, the Kansokyo Takeda Historical Museum is located 7km east of Kobe, Japan. While externally it was modeled on the English Tudor style, its core structure was built of wood in a unique Japanese style, giving it both strength and the flexibility to withstand earthquakes.


WHO WE ARE

Takeda is a **patient-focused**, innovation driven global pharmaceutical company that builds on a distinguished **236-year history**. Our mission is to strive towards **better health** and a **brighter future** for people worldwide through leading innovation in medicine. Established by our founding spirit and integral to every part of our business, **Takeda-ism** and **our priorities** guide us in our efforts to achieve our **Vision 2025**.



Putting patients first for over two centuries

'Takeda-ism' & Our Priorities




We make decisions and take actions by focusing on our four priorities in this order:

- 1 Putting the patient at the center
- 2 Building trust with society
- 3 Reinforcing our reputation
- 4 Developing the business

OUR HERITAGE, OUR FUTURE

Serving the needs of patients through leading innovation in medicine

In 1781, Chobei Takeda I began selling traditional herbal medicines in Osaka, Japan. Takeda's founder gained a reputation for business integrity & quality products, characteristics embedded into the corporate philosophy which still guides us today.



DOSHOMACHI, THE MEDICINE DISTRICT

Located in the major trading port of Osaka, Japan, it was here that standards were set for medicinal products and raw materials.

At age 14, Chobei Takeda I was sent here to work as an apprentice for a medicine broker. His diligent work allowed him the opportunity to start his own business.

TAKEDA GARDEN FOR MEDICINAL PLANT CONSERVATION, KYOTO JAPAN

Established in 1933, here Takeda scientists collect, grow and study herbs and other plants with medicinal value from around the world.

Approximately 2,600 species are grown, of which 200 are endangered (as of June 2017).

FOUNDATION

Chobei Takeda I sets up his business in Osaka

1781

PRODUCTION

Pharmaceutical manufacturing begins in Takeda's factory

1895

TAKEDA GARDEN

for Medicinal Conservation opens

1933



1871

INTERNATIONAL TRADE

Takeda pioneers in the importation of western medicines

1914

PROPRIETARY RESEARCH

activities begin

1940

"NORI" PRINCIPLES

which underpin Takeda-ism, are established

CHOBETI V'S PRINCIPLES OF "NORI"

These principles emphasized the importance of social responsibility, and highlighted people as the key to success in business.

These principles continue to guide us today:

- Serve the public
- Work together in harmony
- Make efforts to study deeply
- Esteem plainness
- Observe propriety

PANVITAN®

Japan's first multivitamin product is launched

1950

SHOSHISHA FOUNDATION

is established to support talented students who will contribute to society

1960

TAKEDA SCIENCE FOUNDATION

is established to encourage promising research and science technology

1963

AN ASPIRATION TO CURE CANCER

With a vision to become a global leader in oncology, the acquisition of Millennium Pharmaceuticals strengthens R&D and commercialization, enhancing our pipeline in oncology and inflammatory disease areas.

The products ENTYVIO® (vedolizumab) and NINLARO® (ixazomib) were discovered by Millennium.

MILLENNIUM PHARMACEUTICALS

is acquired by Takeda, enhancing innovation in oncology

2008

TAKEDA INITIATIVE

forms to support the development of healthcare professionals in Africa

2010

ENTYVIO®

ulcerative colitis and Crohn's disease treatment, is approved by the EMA (EU) and the FDA (U.S.)

2014



1954

ALINAMIN®

a Vitamin B₁ derivative, is launched

1962

OUTSIDE JAPAN

Takeda enters foreign markets

1980's – 1990's

EXPANSION OF INTERNATIONAL BUSINESS

accelerates with the launch of: leuprorelin, lansoprazole, candesartan, pioglitazone

2009

Takeda joins the

UNITED NATIONS GLOBAL COMPACT

and in 2011 its LEAD program

2011

NYCOMED ACQUISITION

expands Takeda's global footprint into more than 70 countries worldwide

2015

TAKEDA AND CiRA

unite in T-CiRA to advance the future of regenerative medicine

EXPANSION OF INTERNATIONAL BUSINESS

Having established its position as a leader in the Japanese pharmaceutical industry, Takeda expands into international markets, collaborating across borders for drug discovery, and establish subsidiaries in Asia, Europe and the Americas.

Exports increase, and four innovative products help establish Takeda's position as a global pharmaceutical company.

INTEGRATION OF NYCOMED


This agreement expands Takeda's global footprint into Europe and Emerging Markets, creating a more balanced and stable business. Nycomed's entrepreneurial "can-do" culture aligns seamlessly with Takeda's corporate philosophy of Takeda-ism.

KYOTO UNIVERSITY'S CENTER FOR IPS CELL RESEARCH AND APPLICATION (CiRA) AND TAKEDA ESTABLISH UNIQUE PARTNERSHIP

A 10-year partnership between Takeda and CiRA established to develop clinical applications of iPSC technology to use in cell therapy, drug discovery and drug safety assessments. The program is directed by Professor Shinya Yamanaka of CiRA, a Nobel Laureate in stem cell research.

A RESPONSIVE MODEL FOR CHANGING TIMES

In response to increased patient needs for generic medicines and social demands to control healthcare costs, Takeda changes its business model, establishing the Takeda-Teva joint venture to offer Teva's generic medicines and Takeda's off-patent drugs in Japan. The joint venture also allows us to focus more sharply on developing innovative medicines to tackle tough medical challenges.



NINLARO®

multiple myeloma treatment is approved by the FDA (U.S.)

2015

TAKEDA-TEVA

joint venture takes on off-patent drugs to allow Takeda to focus on innovation

2016

ARIAD PHARMACEUTICALS

acquired by Takeda to further strengthen its global oncology portfolio and pipeline by expanding into solid tumors

2017

TO OUR FUTURE

VISION 2025

The future state of the company we aspire to become by 2025

We serve the needs of our patients, wherever they are. We earn the trust of society and customers through Takeda-ism. We are recognized as best-in-class because of our agility and innovation, qualities that help us build a steady pipeline and deliver growth, year-on-year.



2016

Therapeutic area focus in **R&D IS SHARPENED** to be at the cutting edge of innovation

2016

VISION 2025 is rolled out

2017

ALUNBRIG™ lung cancer treatment is approved by the FDA (U.S.)



02 PEOPLE

Attracting and Developing Talent
Embracing Diversity & Inclusion



With 30,000 employees located across 70+ countries and regions, people are Takeda's biggest asset. Their combined passion, skills and deep knowledge drive every part of our business, and we strive to support them in their individual growth and development.



A MESSAGE FROM OUR CEO

How can we do more for our patients?
Everything at Takeda starts with this question



About Christophe Weber

Representative Director, President & CEO

Joined Takeda in 2014. Christophe brings a wealth of international leadership experience to Takeda with a career that has spanned nine countries. Before joining us, he held many senior executive positions in the pharmaceutical sector.

Born in France. Christophe holds a doctorate in pharmacy and pharmacokinetics from the University of Lyon, France, where he also earned master's degrees in pharmaceutical marketing and accounting & finance.

In our Vision 2025, we set new goals to become the best-in-class global pharmaceutical leader, driving innovation in the selected three areas of Oncology, Gastroenterology, and Central Nervous System, plus Vaccines. I am delighted to say that this year we have made significant progress towards our goal.

It is a privilege to lead this process together with the Takeda Executive Team, and I look forward to bringing better health and a brighter future to many more patients worldwide as our transformation continues.

A handwritten signature in black ink, appearing to read 'Christophe Weber'.

Christophe Weber

Representative Director, President & CEO

TAKEDA EXECUTIVE TEAM (TET)

JAPAN



CHRISTOPHE WEBER
President & CEO



MASATO IWASAKI
Director; President, Japan
Pharma Business Unit



JAMES KEHOE
Director, Chief Financial
Officer



HARUHIKO HIRATE
Corporate Communications
and Public Affairs Officer



**YOSHIHIRO
NAKAGAWA**
Global General Counsel



DAVID OSBORNE
Global Human
Resources Officer

SWITZERLAND



THOMAS WOZNIEWSKI
Global Manufacturing
and Supply Officer



GILES PLATFORD
President, Europe and
Canada Business Unit

US



ANDREW PLUMP
Director, Chief Medical
& Scientific Officer



RAMONA SEQUEIRA
President, U.S. Business
Unit



CHRISTOPHE BIANCHI
President, Global
Oncology Business Unit



RAJEEV VENKAYYA
President, Global
Vaccine Business Unit



GERARD GRECO
Global Quality Officer



RICARDO MAREK
President, Emerging
Markets Business Unit

SINGAPORE

The Takeda Executive Team consists of a diverse group of experienced leaders, selected for their deep expertise in specific areas related to our business. The team is led by the President & CEO, Christophe Weber, and additional members who report directly to him. Each member is responsible for managing one of the following specific functions of the Takeda Group: finance and accounting, human resources, legal, corporate communication, R&D, manufacturing, quality control, each regional business unit of Japan, U.S., Europe & Canada and emerging markets, and each specialty business unit of oncology and vaccines.

DIVERSE PERSPECTIVES LEAD TO INSIGHTFUL SOLUTIONS


Developing our global workforce with around 30,000 employees in 70+ countries

For Takeda, diversity is critical to our work as a research and innovation-based company. We are accelerating our Diversity and Inclusion activities, and aim to become an industry leader, offering every employee the opportunity to thrive, develop and grow based on merit, potential and ambition regardless of gender, age, disability, nationality, race, sexual orientation and gender identity, religion, experience, belief, values, or life-style.



Across Takeda, our employees bring together many different elements — experiences, backgrounds, nationalities, cultures — that together create a stronger whole.

Takeda's employee distribution



70+ COUNTRIES



30,000 EMPLOYEES



30+ LANGUAGES AND DIALECTS SPOKEN

OUR DIVERSITY PROGRAMS


- Hanamizuki, a career support network through which women can help each other develop professionally (Japan).
- A flexitime program to allow employees to work where and when they can perform at their best (Japan).
- A fast-track career process for promotion of employees who demonstrate high performance early in their careers (Japan).
- Hosting the Takeda U.S. Diversity & Leadership Symposium Week (U.S.).

TALENT DEVELOPMENT

Our Strength comes from within

Takeda fosters a collaborative and stimulating work environment filled with opportunity and the chance to make a difference in people's lives.

Our significant investment in training offers everyone the opportunity to work at the highest levels of our industry, with fast-track programs accelerating the progress of high-potential candidates.



OUR DEVELOPMENT PROGRAMS

Takeda Leadership Behaviors
A new set of expectations for transformational leadership

President's Forum
Takeda's executive management team personally nurture talented people to lead the company in the future

Takeda Leadership Program
Elevating leadership capability through examination of internal and external perspectives on business

Accelerator Program
Elevating leadership capability through examination of internal and external perspectives on business

Global Induction Forum
Induction training for recently hired senior leaders



03 R&D

How our innovation transforms lives




Innovation is at the heart of our R&D. Our researchers and scientists are striving to bring scientific breakthroughs from the lab to patients worldwide.

OUR RESEARCH

A world-class & worldwide R&D organization with focused therapeutic areas. Takeda R&D continues its transformation, driving our patient-centric approach and commitment to deliver innovation.

We innovate with a focus on three therapeutic areas - oncology, gastroenterology (GI), and the central nervous system (CNS). We also leverage our world-class capabilities to develop vaccines to address critical public health threats using novel development platforms, and collaborate with leading partners.



Oncology

We endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation, and our passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies.

Please visit takedaoncology.com for more information.



Gastroenterology

For more than 25 years, Takeda has focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs in gastroenterology (GI).

Takeda is leading in areas of GI associated with high unmet needs, such as inflammatory bowel disease, GI acid-related diseases and GI motility disorders.



CENTRAL NERVOUS SYSTEM CNS

CNS disorders are complex multifaceted conditions that affect the spectrum of mental health.

We are driven to provide novel therapies for people with psychiatric, neurological and rare central nervous system (CNS) disorders who lack adequate treatment options.



Vaccines

Vaccines have transformed global public health. Our world-class vaccine team is addressing unmet medical needs through vaccine development against infectious diseases, while using innovative development platforms and collaborating with leading partners.


PARTNERSHIPS AND COLLABORATIONS

We focus on disease areas where patient need is great, where we can build upon our deep scientific expertise, and where we intend to continue discovering innovative new medicines.



A unique partnership between Kyoto University's Center for iPS Cell Research and Takeda, aspiring to transform the future of medicine using iPS cells

STRATEGIC PARTNERSHIPS

 **50+** in the past 2 years
(AS OF JULY 2017)

SHONAN HEALTH INNOVATION PARK

Aspiring to become the leading hub for Japan's biopharmaceutical ecosystem

AXCELEAD

SCOHIA PHARMA

T-CiRA

Not all-inclusive. All trademarks and registered trademarks are the property of their respective owners

FUNCTIONAL PARTNERSHIPS

PRA Health Sciences
Bushu Pharmaceuticals

ASSET EXTERNALISATION

Myovant Sciences
Cerevance
SCOHIA PHARMA



T-CiRA aims to deliver innovative therapies to patients facing serious and life-threatening conditions, including:

- Cancer
- Heart failure
- Neurodegenerative disorders
- Type 1 diabetes
- Intractable muscle diseases

This research also aims to develop medicines and cell therapies using iPS cells.

A 10-year partnership between Takeda and CiRA, the world's first institute dedicated to pioneering iPS cells research and application, based at Kyoto University Japan, has been established to develop clinical applications of iPSC technology to use in cell therapy, drug discovery and drug safety assessments.

The T-CiRA program, based at Takeda's Shonan Research Center in Fujisawa, Japan, is directed by Professor Shinya Yamanaka of CiRA, a Nobel Laureate in stem cell research.


04 BUSINESS PERFORMANCE

Best practice for better performance



Construction is on-going: Takeda's new global headquarters building located not far from our current headquarters in Nihonbashi, Tokyo, is scheduled to be open for business in Spring 2018.

FY2016 UNDERLYING REVENUE



Overall, Takeda's global underlying revenue for FY2016 totalled 1,716.7 billion yen, an increase of 6.9% over the previous fiscal year.

FY2016 results exceeded guidance

- | | | |
|--|--|--|
| <p>Grow portfolio</p> <ul style="list-style-type: none"> Underlying Revenue +6.9%, every region growing Growth Drivers +14.7%, Entyvio 146.5 Bn yen | <p>Rebuild pipeline</p> <ul style="list-style-type: none"> Significant progress in R&D transformation Over 50 collaborations in 18 months | <p>Boost profitability</p> <ul style="list-style-type: none"> Underlying CE growth +24.2% Underlying CE margin +180 bps ROE is recovering: 6.0% in FY16 (+2.1pp from FY15) |
|--|--|--|

Note: "Underlying growth" compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures from both periods • CE="Core Earnings" is calculated by taking reported Gross Profit and deducting SG&A expenses and R&D expenses. In addition, certain other items that are non-core in nature and significant in value may also be adjusted • bps=basis point: one hundredth of a percent • ROE: Return on equity

TAKEDA'S GROWTH DRIVERS

Revenue growth was led by growth drivers +15%

These four areas now account for 55% of total Takeda revenue

+14.7%

UNDERLYING REVENUE GROWTH



GASTROENTEROLOGY
+33.5%

KEY PRODUCTS

- ENTYVIO
- TAKECAB
- AMITIZA
- DEXILANT
- LANSOPRAZOLE



ONCOLOGY
+7.5%

KEY PRODUCTS

- NINLARO
- ADCETRIS
- ICLUSIG
- VECTIBIX
- LEUPRORELIN
- VELCADE



CENTRAL NERVOUS SYSTEM
+26.7%

KEY PRODUCTS

- TRINTELLIX
- ROZEREM
- REMINYL
- COPAXONE



EMERGING MARKETS
+4.5%

KEY MARKETS

Russia, Brazil, and China are key contributing markets to the growth

CORPORATE SOCIAL RESPONSIBILITY (CSR)

Takeda's CSR is rooted in patient-centricity and operating a pharmaceutical business that creates outstanding products, as well as improving sound business processes to promote a sustainable society

LONG-TERM COMMITMENT

¥4.2 bn



Donation amount for Great East Japan Earthquake assistance

Period for operating recovery support programs by NGOs and NPOs through Takeda's contributions: 2011-2020



Number of 10-year CSR programs

PREVENTION



9

Number of CSR programs focused on disease prevention in developing countries to contribute to the health of communities

PARTICIPATION

8,400+

Takeda employees around the world actively voted to select our global CSR partnership programs starting 2017

Partnerships for Sustainable Development Goals (SDGs)

As a UNGC LEAD company, Takeda will work toward the achievement of SDGs together with partners in the international community to promote better health for people.



Takeda is committed to all SDGs – in particular Goal 3, promoting good health & well-being.



TAKEDA GLOBAL CSR PROGRAM

Employee votes determine our global CSR programs. Takeda implements global CSR programs that emphasize “Prevention for Health in Developing and Emerging Countries”.

2016



10 YEARS



Global Measles Vaccination for Children

Aiming to help vaccinate 5,400,000 children.

BUDGET 1 billion yen **TERM** 10 years
LAUNCH 2016 **AREA** Approximately 40 countries in Africa, Asia and Latin America



5 YEARS



Community Health Workers Training for Maternal and Child Health

Training 1,400 health workers, impacting 500,000 people.

BUDGET 500 million yen **TERM** 5 years
LAUNCH 2016 **AREA** India, Bangladesh, Nepal, Afghanistan



5 YEARS



Maternal and Newborn Health for Ethnic Minorities

Providing 150,000 village people including 40,000 women and children in ethnic minorities with healthcare education, training and services.

BUDGET 250 million yen **TERM** 5 years
LAUNCH 2016 **AREA** Myanmar, Vietnam, Laos

2017



5 YEARS



“The First 1000 Days” Health and Nutrition program

Support access to quality health services and nutrition to a total of 1.3 million mothers and children

BUDGET 1 billion yen **TERM** 5 years
LAUNCH 2017 **AREA** Benin, Madagascar, Rwanda



5 YEARS



Holistic health program for refugee crisis of South Sudan and Syria

BUDGET 1 billion yen **TERM** 5 years
LAUNCH 2017 **AREA** Ethiopia, Uganda, Sudan, South Sudan, Egypt, Jordan, Lebanon



5 YEARS



Protecting the lives of pregnant women in Africa

BUDGET 750 million yen **TERM** 5 years
LAUNCH 2017 **AREA** Tanzania, Kenya, Zambia, Ghana

ACCESS TO MEDICINES

Takeda's Access to Medicines (AtM) Strategy

Improving access to care and treatment for patients in parts of the world with the highest unmet medical needs



Launched AtM strategy at the sixth annual Tokyo International Conference of Africa's Development which took place in Kenya in August 2016

Serving the needs of patients, wherever they are: Takeda actively participates in global health partnerships

KEY HIGHLIGHTS AS OF JUNE 2017

LAUNCHED AT THE WORLD ECONOMIC FORUM IN DAVOS, JANUARY 2017

- Sub-Saharan Africa** Established a not-for-profit approach in Sub-Saharan Africa, where we are the first Japanese pharmaceutical company to have a physical presence in the region
- PAPs** Implementing **Patient Assistance Programs (PAPs)** using innovative, affordability-based approaches
- Blueprint for Success** Convened **"Blueprint for Success" Summit** for over 100 global health experts to identify partnership models that improve access to medicines and save lives



Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving care for non-communicable diseases (e.g. cancer, hypertension, diabetes) in low income countries.



Coalition for Epidemic Preparedness innovations (CEPI) is a partnership of public, private, philanthropic and civil organizations to stimulate, finance and coordinate vaccine development against priority threats, particularly when development is unlikely to occur through market incentives alone.

236 years after our foundation, we feel great humility in knowing that our medicines and vaccines now reach people across the globe — but we know we can do more.

Please visit our corporate website for more on who we are, what we do and what we stand for.

Our Stories:

Takeda.com/our-stories

Our Positions & Guidelines:

Takeda.com/who-we-are/company-information/Positions_Guidelines

Our Business:

Takeda.com/what-we-do

For further information, please contact:

Osaka

1-1, Doshomachi 4-chome Chuo-ku,
Osaka-shi, Osaka 540-8645, Japan

Tel: +81-6-6204-2111

Fax: +81-6-6204-2880

Tokyo

12-10, Nihonbashi 2-chome Chuo-ku,
Tokyo 103-8668, Japan

Tel: +81-3-3278-2111

Fax: +81-3-3278-2000

URL

takeda.com



Important Note

This Corporate Profile contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.

ALINAMIN®, ALUNBRIG™, AZILVA®, DEXILANT®, ENTYVIO®, ICLUSIG®, LUPRON®, NINLARO®, PANVITAN®, ROSEREM®, TAKECAB® and VELCADE® are either registered trademarks or trademarks of Takeda Pharmaceutical Company Limited and/or its affiliates in Japan and/or other countries. ADCETRIS® is a registered trademark of Seattle Genetics, Inc. TRINTELLIX® is either a registered trademark or a trademark of H. Lundbeck A/S in Denmark and/or other countries. AMITIZA® is a registered trademark or a trademark of Sucampo AG in the United States and/or other countries. COPAXONE® is a registered trademark or a trademark of Teva Pharmaceutical Industries Ltd in Israel and/or other countries. VECTIBIX® is either a registered trademark or a trademark of Immunex Corporation in the United States and/or other countries.

Takeda is proud of its 236-year heritage, which defines who we are and where we are going. We are inspired and motivated by our patients: their stories, their lives their hopes for **better health** their dreams for a **brighter future**



For more information,
visit [Takeda.com](https://www.takeda.com)